Association of Genetically Enhanced Lipoprotein Lipase–Mediated Lipolysis and Low-Density Lipoprotein Cholesterol–Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes

IMPORTANCE: Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs would require large outcome t...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:JAMA Cardiol
Main Authors: Lotta, Luca A., Stewart, Isobel D., Sharp, Stephen J., Day, Felix R., Burgess, Stephen, Luan, Jian’an, Bowker, Nicholas, Cai, Lina, Li, Chen, Wittemans, Laura B. L., Kerrison, Nicola D., Khaw, Kay-Tee, McCarthy, Mark I., O’Rahilly, Stephen, Scott, Robert A., Savage, David B., Perry, John R. B., Langenberg, Claudia, Wareham, Nicholas J.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Medical Association 2018
נושאים:
Original Investigation
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217943/
https://ncbi.nlm.nih.gov/pubmed/30326043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2018.2866
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים